Constipation Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the constipation treatment market size is projected to expand from USD 13.22 billion in 2025 and USD 13.97 billion in 2026 to USD 18.84 billion by 2031, registering a CAGR of 6.17% between 2026 to 2031.

This report is Segmented by Drug Class (Bulk-Forming Agents, and More), Disease Type (Chronic Idiopathic Constipation, and More), Prescription Type (Over-The-Counter, and More), Route of Administration (Oral, and More), Patient Type (Adult, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Constipation Treatment Market Trends and Insights

Aging Population Boosts Chronic-Use Demand

People aged 65 and above numbered 761 million in 2025 and are projected to reach 994 million by 2030, a shift that raises baseline constipation prevalence to more than 26%. Long-term care facilities mandate prophylactic osmotic or bulk-forming agents, turning these products into recurring, annuity-style prescriptions. Japan, where 29.1% of citizens are older than 65, reported a 14% rise in laxative scripts among those over 75 during 2025. Higher Parkinson's and diabetes incidence further entrenches multi-year regimens. Manufacturers answer with low-sodium, palatable formulas aligned with the 2024 Beers Criteria update, which flags high-osmolarity products for deprescribing.

Opioid Prescription Surge Driving OIC Therapies

The United States dispensed 142.2 million opioid prescriptions in 2024, only 7% below 2023, sustaining a large cohort at risk for opioid-induced constipation. Up to 81% of chronic-opioid patients experience OIC, yet fewer than one-quarter receive a peripherally acting mu-opioid receptor antagonist, leaving an undertreated pool that often presents in emergency care for fecal impaction. European regulators widened methylnaltrexone labeling in 2024, enlarging the non-cancer pain segment. Physicians increasingly redirect to GC-C agonists like linaclotide off-label to bypass prior-authorization barriers, spurring interest in fixed-dose opioid-laxative combinations that minimize therapeutic gaps.

Adverse-Effect & Dependency Fears Curb Long-Term Use

A 2025 FDA surveillance review showed that 19% of chronic stimulant users developed hypokalemia serious enough to require hospitalization. Advocacy groups caution against more than 14 straight days of stimulant use, and cohort data reveal a 34% dose-escalation rate within 18 months, validating dependency concerns. Health Canada's advisory linking high-dose polyethylene glycol to aspiration pneumonia in frail seniors has driven nursing homes toward fiber-based agents despite a slower onset.

Other drivers and restraints analyzed in the detailed report include:

1. E-Commerce Accelerates OTC Laxative Penetration
2. Pipeline Gut-Targeted Neuromodulators Enter Mid-Stage Trials
3. Stricter OTC Stimulant / Sodium-Phosphate Regulations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Stimulant agents accounted for 38.62% of segment revenue in 2025, reflecting their low cost and rapid onset, yet lubricant formulas are projected to grow at a 7.06% CAGR as microencapsulation reduces aspiration risk among elders. Osmotic agents remain first-line in hospital protocols, though their 5.8% growth lags the 6.17% baseline of the constipation treatment market. Secretagogues already command premium pricing, and their patents expiring in 2027-2028 could invite biosimilars that compress margins.

Bulk-forming products enjoy a reputation for "natural" relief but require high fluid intake that deters frail patients. Stool softeners, chiefly docusate, slide after a Cochrane review showed no clear efficacy, leading the American College of Gastroenterology to downgrade them in 2025 guidance. Peripherally acting mu-opioid receptor antagonists occupy a specialized OIC niche but endure payer hurdles that limit uptake compared with off-label GC-C alternatives.

Opioid-induced constipation retained 34.07% of disease-type value in 2025, yet IBS-C is forecast to sprint ahead at a 9.63% CAGR, the fastest among all indications. Chronic idiopathic constipation remains the largest absolute pool but grows more slowly as patients experiment with diet, fiber supplements, and app-based biofeedback.

Rome IV criteria revisions in 2024 effectively expanded the IBS-C population by lowering the symptom-frequency threshold, enlarging the patient pool for GC-C and 5-HT4 agonists. Prucalopride prescriptions surged 27% in 2025 after pediatric European approval stimulated brand visibility. Neurologic constipation continues to be underserved, reflecting split care pathways between neurology and gastroenterology practices.

Complete Report Scope:

• By Drug Class
  • Bulk-Forming Agents
  • Osmotic Agents
  • Stimulant Agents
  • Stool Softeners / Emollients
  • Lubricant Agents
  • Secretagogues (ClC-2, GC-C)
  • Other Drug Classes
• By Disease Type
  • Chronic Idiopathic Constipation (CIC)
  • Irritable Bowel Syndrome-C (IBS-C)
  • Opioid-Induced Constipation (OIC)
  • Post-surgical & Neurologic Constipation
• By Prescription Type
  • Over-the-Counter (OTC)
  • Prescription Drugs
• By Route of Administration
  • Oral
  • Rectal
  • Parenteral
• By Patient Type
  • Adult
  • Geriatric
  • Pediatric
• By Distribution Channel
  • Hospital Pharmacies
  • Retail / Drug Stores
  • Online Pharmacies & DTC Subscriptions
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 39.43% of 2025 revenue on the back of high per-capita health spending and entrenched opioid prescribing that feeds the OIC segment. Canada expanded linaclotide coverage in its two largest provinces during 2024, prompting a 23% rise in prescriptions. Mexico remains bifurcated: metropolitan centers mirror U.S. treatment patterns, while rural areas lean on herbal senna, leaving prescription penetration at 34% of diagnosed cases.

Germany, the United Kingdom, and France supply 62% of regional turnover, but single-payer cost controls push clinicians toward generics. Takeda's newly approved 5-HT4 agent still awaits favorable price agreements in Italy and Spain, delaying uptake. NICE guidance updates that emphasize fiber and lifestyle adjustment dampen prescription volume in the United Kingdom.

Asia-Pacific posts the fastest regional CAGR at 11.27%. China's decision to add linaclotide to provincial reimbursement lists in 2024, India's low-priced generic GC-C launches, and Japan's super-aged demographic collectively propel growth. Australia's stimulant pack-size caps inadvertently shift chronic users to prescription items, while South Korea leverages telemedicine to broaden specialist access.

Middle East and Africa together represent a modest 7% share but record steady expansion as Gulf states upgrade health infrastructure. South America grows at 6.9%; Brazil's approval of plecanatide in 2024 and local generic launches keep prices accessible. Economic volatility in Argentina continues to push consumers toward locally made stimulants.

1. Abbvie
2. Abbott Laboratories
3. Ardelyx Inc.
4. AstraZeneca
5. Bausch Health (Salix)
6. Bayer
7. Beutlich Pharmaceuticals
8. Boehringer Ingelheim
9. Dr. Reddy's Laboratories
10. GlaxoSmithKline
11. Ironwood Pharmaceuticals
12. Johnson & Johnson
13. Mallinckrodt Pharma
14. Norgine B.V.
15. Prestige Consumer Healthcare
16. Procter & Gamble
17. Sanofi
18. Sun Pharmaceuticals Industries
19. Takeda Pharmaceuticals
20. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support